EGFR and non-small cell lung carcinoma: In recent years, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have been approved to treat patients with NSCLC that harbors an activating mutation of EGFR [2].